Home Thomson StreetEvents

Alnylam Pharmaceuticals Inc â€œRNAi Roundtableâ€ Webcast Series: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis Transcript

Published Sep 03, 2020

19 pages (14780 words) — Published Sep 03, 2020

Price US$ 54.00 | Buy this Report Now

About This Report

Abstract:

Edited Transcript of ALNY.OQ conference call or presentation 3-Sep-20 4:00pm GMT

Brief Excerpt:

...Good afternoon, everyone. Thank you for joining us today for this RNAi Roundtable, where we'll be discussing patisiran and vutrisiran development for the treatment of transthyretin-mediated amyloidosis. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are Eric Green, Senior Vice President and General Manager of the TTR program; John Vest, Vice President of Clinical Research; Rena Denoncourt, Senior Director and Program Leader of the vutrisiran program; and Dr. Nitasha Sarswat, Director of the Infiltrative Cardiomyopathy Program at the University of Chicago Hospital. Before I hand it over to Eric, I'll start with a few brief comments. Today's RNAi Roundtable is the fourth in a series of roundtable webinars that we've been hosting over the past few months to review progress across our various programs. Today's event is expected to run approximately 75 minutes. Eric will moderate a Q&A session at the conclusion of...

Report Type:

Transcript

Source:

Thomson StreetEvents

Company:

Alnylam Pharmaceuticals Inc

Ticker

ALNY.OQ

Time

4:00pm GMT

Format:

PDF

The following is excerpted from the question-and-answer section of the transcript. (Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Alnylam Pharmaceuticals Inc at Chardan Genetic Medicines Conference (Virtual) Transcript – 2020-10-05 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 5-Oct-20 8:15pm GMT

Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript – 2020-09-17 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 17-Sep-20 1:10pm GMT

Alnylam Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript – 2020-09-16 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 16-Sep-20 7:20pm GMT

Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript – 2020-09-15 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 15-Sep-20 1:30pm GMT

Alnylam Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript – 2020-09-10 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 10-Sep-20 2:45pm GMT

Alnylam Pharmaceuticals Inc â€œRNAi Roundtableâ€ Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type I Transcript – 2020-08-10 – US$ 54.00 – Edited Transcript of ALNY.OQ conference call or presentation 10-Aug-20 6:00pm GMT

Alnylam Pharmaceuticals Inc Q2 2020 Earnings Call Summary – 2020-08-06 – US$ 54.00 – Edited Brief of ALNY.OQ earnings conference call or presentation 6-Aug-20 12:30pm GMT

Alnylam Pharmaceuticals Inc Q2 2020 Earnings Call Transcript – 2020-08-06 – US$ 54.00 – Edited Transcript of ALNY.OQ earnings conference call or presentation 6-Aug-20 12:30pm GMT

Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Napa Healthcare Conference (Virtual) Transcript – 2020-06-24 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 24-Jun-20 5:30pm GMT

Alnylam Pharmaceuticals Inc to Discuss Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress Summary – 2020-06-07 – US$ 54.00 – Edited Brief of ALNY.OQ conference call or presentation 7-Jun-20 12:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author

Cite this Report


MLA:	Thomson StreetEvents. "Alnylam Pharmaceuticals Inc â€œRNAi Roundtableâ€ Webcast Series: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis Transcript" Sep 03, 2020. Alacra Store. May 02, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Alnylam-Pharmaceuticals-Inc-RNAi-Roundtable-Webcast-Series-Patisiran-Vutrisiran-in-Development-for-the-Treatment-of-Transthyretin-Mediated-Amyloidosis-T13375842>

APA:	Thomson StreetEvents. (2020). Alnylam Pharmaceuticals Inc â€œRNAi Roundtableâ€ Webcast Series: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis Transcript Sep 03, 2020. New York, NY: Alacra Store. Retrieved May 02, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Alnylam-Pharmaceuticals-Inc-RNAi-Roundtable-Webcast-Series-Patisiran-Vutrisiran-in-Development-for-the-Treatment-of-Transthyretin-Mediated-Amyloidosis-T13375842>